Use of mitoxantrone to treat multiple sclerosis

Multiple Sclerosis Therapeutics

Volumn , Issue , 2007, Pages 457-479

  Edan, Gilles ^a   Morrissey, Sean P ^a   Hartung, Hans Peter ^b  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38049028002     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (96)

1. Alberts DS, Peng YM, Bowden GT, et al. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 1985; 3: 101-7
2. Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 41: 400-99
3. Lenk H, Müller U, Tanneberger S. Mitoxantrone: mechanisms of action, antitumor activity, pharma-cokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 1987; 7: 1257-64
4. Koeller J, Eble M. Mitoxantrone: a novel anthracycline derivative. Clin Pharm 1998; 7: 574-81
5. Shenkenberg TD, Von Hoff D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 1986; 105: 67-81
6. Wang BS, Murdock KC, Lumanglas AL, et al. Relationship of chemical structures of anthraquinones with their effects on the suppression of immune responses. Int J Immunopharm 1987; 9: 733-9
7. Wang BS, Lumaglas AL, Ruszala-Mallon VM, et al. Induction of alloreactive immuno-suppression by 1,4-bis [(2-aminoethyl)amino]-5,8-dihydroxy-9,10-anthracenedione dihydrochloride (CL 232,468). Int J Immunopharmacol 1984; 6: 475-82
8. Schneider T, Kupiec-Weglinski J, Towpik E, et al. Mitoxantrone: an immunosuppressive agent potentially useful in organ transplantation. FedProc 1985; 44: 1681
9. Bisteau M, Devos G, Brucher JM, Gonsette RE. Prevention of subacute experimental allergic ence-phalomyelitis in guinea-pigs with desferrioxamine, isoprinosine and mitoxantrone. In Gonsette RE, Delmotte P, eds. Recent Advances in Multiple Sclerosis Therapy. International Congress Series. Amsterdam: Elsevier Science Publishers, 1989; 863: 299-300
10. Levine S, Saltzman A. Regional suppression therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuro-immunol 1986; 13: 175-81
11. Lublin FD, Lavasa M, Viti C, Knobler RL. Suppression of acute and relapsing experimental allergic encephalo-myelitis with mitoxantrone. Clin Immunol Immuno-pathol 1987; 45: 122-8
12. Ridge SC, Sloboda AE, McReynolds RA, et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 1985; 35: 35-42
13. Watson CM, Davison AN, Baker D, et al. Suppression of demyelination by mitoxantrone. Int J Immunopharmacol 1991; 13: 923-30
14. Gonsette RE, Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 1990; 40 (Suppl 1): 261 (abstr 537P)
15. Kappos L, Gold R, Künstler E, et al. Mitoxantrone in the treatment of rapidly progressive MS: a pilot study with serial gadolinium-enhanced MRI. Neurology 1990; 40 (Suppl 1): 261 (abstr 539P)
16. Mauch E, Kornhuber HH, Krapi H, et al. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psych Clin Neurosci 1992; 242: 96-102
17. Noseworthy JH, Hopkins MB, Vandervoort MK, et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993; 43: 1401-6
18. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylpre-dnisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-18
19. Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-25
20. Mauch E, Eisenmann S, Hahn A, et al. Mitoxantrone in the treatment of patients with multiple sclerosis: a large single center experience. Mult Scler 1999; 5 (Suppl 1): P366
21. Bowden GT, Roberts R, Alberts DS, et al. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. Cancer Res 1985; 45: 4915-20
22. Bhalla K, Ibrado AM, Tourkina E, et al. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 1993; 82: 3133-40
23. Bellosillo B, Colomer D, Pons G, Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 1998; 100: 142-6
24. Bailly JD, Skladanowski A, Bettaieb A, et al. Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis. Leukemia 1997; 11: 1523-32
25. Holden JA. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs. Ann Clin Lab Sci 1997; 27: 402-12
26. Smith PJ, Blunt NJ, Desnoyers R, et al. DNA topoisomerase II-dependent cytoxicity of alkylamino-anthraquinones and their N-oxides. Cancer Chemother Pharmacol 1997; 39: 455-61
27. Fox ME, Smith PJ. Long-term inhibition of DNA synthesis and persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer 1990; 50: 5813-18
28. Fisher GR, Patterson LH. DNA strand breakage by peroxidase-activated mitoxantrone. J Pharm Pharmacol 1990; 43: 65-8
29. Basra J, Wolf CR, Brown JR, Patterson LH. Evidence for human liver mediated free-radical formation by doxorubicin and mitoxantrone. Anticancer Drug Design 1985; 1: 45-52
30. 2*) radicals. Chem Res Toxicol 1997; 10: 1325-30
31. Panousis C, Kettle AJ, Phillips DR. Neutrophil-mediated activation of mitoxantrone to metabolites which form adducts with DNA. Cancer Lett 1997; 113: 173-8
32. Fidler JM, Quinn DeJoy S, Gibbons JJ Jr. Selective immunomodulation by the anti-neoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986; 137: 727-32
33. Fidler JM, Quinn DeJoy S, Smith FR, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986; 136: 2747-54
34. Gonsette RE. Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler 1996; 1: 329-32
35. Zaffaroni M, Ghezzi A, Baldini SM, Zibetti A. Effetti immunosuppressori del mitoxantrone nella sclerosi multipla cronica-progressiva. In Ghezzi A, et al., eds. La Ricerca sulla Sclerosi Multipla in Italia. Salerno: Momento Medico, 1995: 112-14
36. Chan A, Weilbach FX, Toyka KV, Gold R. Mito-xantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005; 139: 152-8
37. Neuhaus O, Wiendl H, Kieseier BC, et al. Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005; 168: 128-37.
38. Stewart DJ, Green RM, Mikhael NZ, et al. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 1986; 70: 1255-61
39. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomised placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: a 24-month clinical and MRI outcome. J Neurol 1997; 244: 153-9
40. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis; a randomised, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173-80
41. Krapf H, Mauch E, Fetzer U, et al. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiol 1995; 37: 113-19
42. Krapf H, Morrissey SP, Zenker O, et al. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005; 65: 690-6
43. Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991; 54: 683-8
44. Dukart G, Barone JS. An overview of cardiac episodes following mitoxantrone administration. Cancer Treat Symp 1984; 3: 35-41
45. Gams RA, Wesler MJ. Mitoxantrone cardiotoxicity: results from Southeastern Cancer Study Group. Cancer Treat Symp 1984; 3: 31-3
46. Foster BJ, Lev L, Bergemann C, et al. Cardiac events in phase II trials with mitoxantrone. Cancer Treat Symp 1984; 3: 43-6
47. Posner LE, Dukart G, Goldberg J, et al. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 1985; 3: 123-32
48. Fountzilas G, Afthonidis D, Geleris P, et al. Cardiotoxicity evaluation in patients treated with a mitoxantrone combination as adjuvant chemotherapy for breast cancer. Anticancer Res 1992; 12: 231-4
49. Herman EH, Zhang J, Hasinoff BB, et al. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J Mol Cell Cardiol 1997; 29: 2415-30
50. Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res 1983; 43: 4543-51
51. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987; 19: 817-28
52. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197: 165-7
53. Robison TW, Giri SN. Effects of chronic administration of doxorubicin on myocardial beta-adrenergic receptors. Life Sci 1986; 39: 731-6
54. Singal PK, Pierce GN. Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol 1986; 250: H419-25
55. Ehrke MJ, Maccubbin D, Ryoyama K, et al. Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res 1986; 46: 54-60
56. Hasinoff BB. Chemistry of dexrazoxane and analogues. Semin Oncol 1998; 25 (Suppl 10): 3-9
57. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980; 65: 128-35
58. Leray E, Coustans M, Le Page E, et al. Mortality in multiple sclerosis: results from the Rennes' experience. Presented at the 20th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 9th Annual Meeting of Rehabilitation in MS, Vienna, Austria, October 2004: abstr P275
59. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909-13
60. Goffette S, van Pesch V, Vanoverschelde JL, et al. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J Neurol 2005; 252: 1217-22
61. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-7
62. Crossley RJ. Clinical safety and tolerance of mitoxantrone. Semin Oncol 1984; 11 (Suppl 1): 54-8
63. Pedersen-Bjergaard J, Andersen MK, Larsen SO, et al. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol 1998; 16: 1897-8
64. Andersson M, Philip P, Pedersen-Bjergaard J. High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer. Cancer 1990; 65: 2460-4
65. van Leeuwen FE. Second cancers. In Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincott-Raven, 1997: 2773-96
66. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400: 233-55
67. Vicari AM, Ciceri F, Folli F, et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998; 12: 441-2
68. Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002; 8: 441-5
69. Cattaneo C, Almici C, Borlenghi E, et al. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 2003; 17: 985-6
70. Mogenet I, Simiand-Erdociain E, Canonge JM, Pris J. Acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis. Ann Pharmacother 2003; 37: 747-8
71. Heesen C, Bruegmann M, Gbdamosi J, et al. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mito-xantrone. Mult Scler 2003; 9: 213-14
72. Jaster JH, Niell HB, Dohan FC Jr, Smith TW. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2003; 60: 1399-1400; author reply 1400
73. Brassat D, Recher C, Waubant E, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002; 59: 954-5
74. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-29
75. Meistrich ML, Wilson G, Mathur K, et al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol 1997; 15: 3488-95
76. Manandhar M, Cheng M, Iatropoulos MJ, Noble JF. Genetic toxicology profile of the new antineoplastic drug mitoxantrone in the mammalian test systems. Arzneimittelforschung 1986; 36: 1375-9
77. Goodkin DE, Stead R, Flanders K. Registry to evaluate mitoxantrone effects in worsening MS (the RENEW Study): a work in progress. Mult Scler 2001; 7: S129
78. http://afssaps.sante.fr/index.htm
79. European Study Group on Interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7
80. Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788-95
81. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504
82. Cohen JA, Cutter GR, Fischer JS, et al.; IMPACT Investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87
83. Le Page E, Coustans M, Mauduit N, et al. Induction treatment with monthly mitoxantrone- methylprednisolone for 6 months in worsening relapsing-remitting multiple sclerosis: the clinical benefit lasts at least 4 years. Mult Scler 2001; 7 (Suppl 1): S63
84. Debouverie M, Vandenberghe N, Morrissey SP, et al. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis. Mult Scler 2004; 10: 407-12
85. Coustans M, Le Page E, Leray E, et al. Clinical impact of mitoxantrone in 64 primary progressive multiple sclerosis. Presented at the 55th Annual Meeting of the American Academy of Neurology, Honolulu, HI, March-April 2003: abstr S31.002
86. Kita M, Cohen JA, Fox RJ, et al. A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis. Presented at the 56th Annual Meeting of the American Academy of Neurology, San Francisco, CA, April-May 2004: abstr S12.004
87. Gonsette RE. Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 2003; 206: 203-8
88. Jeffery DR, Chepuri N, Durden D, Burdette J. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 2005; 11:296-301
89. Correale J, Rush C, Amengual A, Goicochea MT. Mitoxantrone as rescue therapy in worsening relapsing- remitting MS patients receiving IFN-beta. J Neuro-immunol 2005; 162: 173-83
90. NeoPharm, www-information: www.twst.com/notes/articles/nah325.html
91. Taylor IW, Bleehen NM. Razoxane-induced polyploidy. Br J Cancer 1978; 38: 143-7
92. Weilbach FX, Chan A, Toyka KV, Gold R. The car-dioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune ence-phalomyelitis. Clin Exp Immunol 2004; 135: 49-55
93. Kita M, Chow E, Reed D. A pilot study of mitoxantrone plus dexrazoxane versus mitoxantrone in patients with relapsing remitting, secondary progressive and progressive relapsing MS. Presented at the 57th Annual Meeting of the American Academy of Neurology, Miami Beach, FL, April 2005: abstr PO5.139
94. Bernitsas E, Wei W, Mikol DD. Suppression of mito-xantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol 2006; 59: 203-9
95. Herman EH, Zhang J, Rifai N, et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone induced cardiotoxicity. Cancer Chemother Pharmacol 2001; 48: 297-304
96. Beer M, Sandstede J, Weilbach F, et al. Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2001; 173: 399-404